Tibotec Presents Interim Findings for TMC435
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008Nearly 90 percent of patients achieve undetectable viral load in Phase IIa trial within 28 days of combined…